Akèy › Kansè nan tete › Minnesota
Etid klinik pou Kansè nan tete nan Minnesota
68 etid pou Kansè nan tete ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
- Rochester42 etid
- Minneapolis27 etid
- Saint Paul12 etid
- Plymouth8 etid
- Duluth7 etid
- Brooklyn Park6 etid
- Bloomington5 etid
- Mankato4 etid
- Saint Cloud4 etid
Tèks ofisyèl etid la (Anglè)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Minnesota Oncology Hematology P A, Minneapolis
- Allina Hlth Cancer Inst Minneapolis, Minneapolis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- ak 48 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 45 · Fanm · Mizajou Oct 1, 2026 · NCT05557877A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Minnesota, Masonic Cancer Center, Minneapolis
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- University of Minnesota Masonic Cancer Center, Minneapolis
- Mayo Clinic Comprehensive Cancer Center, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05868226Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Mayo Clinic, Rochester
Ap rekrite
Laj 30 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT02945579A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Saint Paul
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Mayo Clinic Cancer Center, Rochester
- HealthPartners Frauenshuh Cancer Center, Saint Louis Park
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Minneapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mayo Clinic, Rochester
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Minnesota, Rochester
- Metro-Minnesota Community Clinical Oncology, Saint Louis Park
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Mayo Clinic in Rochester, Minnesota, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Healthpartners Regions Specialty Clinics, Saint Louis Park
- Healthpartners Regions Specialty Clinics, Saint Paul
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Mayo Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Mayo Clinic Health System - Albert Lea, Albert Lea
- Mayo Clinic - Mankato, Mankato
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Metro-Minnesota Community Oncology Research Consortium, Saint Paul
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT03424005A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Marshall, Marshall
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07405801A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Mayo Clinic, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05307705Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Mayo Clinic, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Minnesota Oncology Hematology, P.A., Minneapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- University of Minnesota Medical Center, Minneapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06790693FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07216105The Vanguard Study: Testing a New Way to Screen for Cancer
- Minneapolis VA Medical Center, Minneapolis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- ak 47 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Mayo Clinic, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06488378Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Fanm · Mizajou Aug 27, 2026 · NCT07207564A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
- Mayo Clinic in Rochester, Rochester
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07047872Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Minnesota Oncology Hematology, Maple Grove
- Local Institution - 0372, Minneapolis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Minnesota Oncology, Maple Grove
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 6, 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health Cancer Center, Duluth
- Mayo Clinic Health Systems-Mankato, Mankato
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT04521764Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06562192A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.